Novo Nordisk has announced two major regulatory milestones in the European Union. The company received approval for an oral version of its weight management drug Wegovy, as well as a new 7.2 mg dose pen. Additionally, the company is taking legal action against Eli Lilly regarding misleading GLP-1 advertising campaigns.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.